Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
Authors:
- Ronald M. WittelesRWRonald M. Witteles
- Michael B. FowlerMFMichael B. Fowler
- Melinda L. TelliMTMelinda L. Telli
- 1 July 2011
- journal article
- review article
- Published by Elsevier in Heart Failure Clinics
- Vol. 7 (3) , 333-344
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patientsAnnals of Oncology, 2002
- Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.Journal of Clinical Oncology, 1998
- A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factorsCancer, 1991
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Daunomycin-induced cardiotoxicity in children and adultsThe American Journal of Medicine, 1977
- AdriamycinAnnals of Internal Medicine, 1974
- A clinicopathologic analysis of adriamycin cardiotoxicityCancer, 1973
- Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseasesCancer, 1973